EFFICACY OF LAMIVUDINE IN PATIENTS WITH HBV- RELATED HEPATIC CIRRHOSIS

2012 ◽  
pp. 107-113
Author(s):  
Van Huy Tran ◽  
Hoai Phong Nguyen
Keyword(s):  
Viral Replication ◽  
Antiviral Therapy ◽  
Hepatic Cirrhosis ◽  
Hbeag Seroconversion ◽  
Hbv Dna ◽  
Hbeag Loss ◽  
Complications Of Cirrhosis

Background: The recent studies concerning antiviral therapy in HBV-related cirrhosis showed the promising results. This study is aimed at assessing efficacy of lamivudine in patients with HBV-related cirrhosis. Patients and methods: 41 patients with HBsAg positive-cirrhosis and evidence of viral replication were enrolled in the study. Lamivudine is given 100 mg per day and the follow-up is 12 months. Results: The rates of HBV DNA undetectable was 58.53%, 68.29% and 87.80% after 36.6 and 12 months, respectively. The rate of HBeAg loss and HBeAg seroconversion are 57.14% and 35.71%. Child-Pugh scores decreased significantly after 6 and 12 months. The complications of cirrhosis were infrequent. Conclusion: Lamivudine appeared effective and safe in HBV-related hepatic cirrhosis.

scholarly journals Effect of viral replication and liver fibrosis on all-cause mortality in HIV/HBV coinfected patients: a retrospective analysis of a 15-year longitudinal cohort

2021 ◽  
Author(s):  
Lorenza N C Dezanet ◽  
Raisha Kassime ◽  
Patrick Miailhes ◽  
Caroline Lascoux-Combe ◽  
Julie Chas ◽  
...  
Keyword(s):  
Liver Fibrosis ◽  
Viral Replication ◽  
Hbv Dna ◽  
Prognostic Indicators ◽  
Rna Detection ◽  
Viral Loads ◽  
Hiv Rna ◽  
Hbv Replication ◽  
All Cause Mortality

Background In patients co-infected with HIV and hepatitis B virus (HBV), widespread tenofovir (TDF)-containing antiretroviral therapy (ART) has led to substantial decreases in HBV-DNA and HIV-RNA detection. However, the link between viral replication, liver fibrosis, and mortality remains unclear. Methods 300 HIV-HBV co-infected patients undergoing ART were prospectively followed. Virological and clinical data were obtained at baseline and every 6-12 months. We quantified the association between HBV-DNA, HIV-RNA, and liver fibrosis with risk of all-cause mortality using a joint longitudinal-survival model. Viral detection, viral loads, and time-averaged cumulative viral loads of HIV and HBV were modeled as three separate exposures. Results During a median 10.5 years (IQR=4.0-14.6), the proportion undergoing TDF-containing ART (baseline=18.7%, end of follow-up=79.1%) and with undetectable HBV-DNA (baseline=36.7%, end of follow-up=94.8%) substantially increased. HIV-RNA was mostly undetectable during follow-up (76.6%). 42 participants died (incidence rate=1.30/100person-years, 95%CI=0.96-1.76). The leading causes of death were non-AIDS/non-liver-related malignancies (28.6%), closely followed by liver-related (16.7%), AIDS-related (16.7%), and other (16.7%). All-cause mortality was associated with HBV-DNA viral load (adjusted-HR per log10IU/mL=1.41, 95%CI=1.04-1.93, p=0.03) or time-averaged cumulative HBV-DNA (adjusted-HR per log10IU-years=1.37, 95%CI=1.03-1.83, p=0.03), but not undetectable HBV-DNA (adjusted-HR=0.30, 95%CI=0.08-1.09, p=0.08). Liver fibrosis at baseline also significantly increased mortality rates (adjusted-HR=2.35, 95%CI=1.16-4.76, p=0.02). No significant association between HIV-RNA replication and mortality was observed. Conclusions Concurrent and historical HBV replication and liver fibrosis are important drivers of all-cause mortality in largely TDF-treated HIV-HBV co-infected patients, despite one-fifth of deaths being liver-related. HBV-DNA and liver fibrosis remain important prognostic indicators for this patient population.

scholarly journals Antiviral therapy effectively improves liver hemodynamics as evidenced by serum biomarker and contrast-enhanced ultrasound examinations in patients with hepatitis B cirrhosis

PeerJ ◽  
2018 ◽  
Vol 6 ◽  
pp. e5484 ◽  
Author(s):  
Xiaoyong Xu ◽  
Chaoxue Zhang ◽  
Chen Shi ◽  
Naizhong Hu ◽  
Bin Sun ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Portal Vein ◽  
Antiviral Therapy ◽  
Hepatic Vein ◽  
Arrival Time ◽  
Nucleoside Analogs ◽  
Hbv Dna ◽  
Baseline Values ◽  
Liver Hemodynamics

Background and Aims To prospectively evaluate the effects of antiviral therapy on liver hemodynamics in patients with hepatitis B cirrhosis. Methods Seventy consecutive eligible HBV-related cirrhotic inpatients were enrolled in the prospective study. Fifty-two received different nucleoside analogs monotherapy and 18 denied antiviral therapy. Their liver biochemistry profiles and HBV-DNA were measured at the baseline and every 3 months. Peripheral blood vWF and sCD163, as well as liver ultrasound Doppler parameters including portal vein diameter (PVD), portal vein velocity (PVV), portal vein congestion index (PV-CI), hepatic vein damping index (HV-DI), hepatic arterial arrival time (HAAT), hepatic vein arrival time (HVAT) and intrahepatic cycle time (HV-HA), were measured at the baseline and the follow-up periods. Results In the antiviral group, all patients achieved complete virologic and liver biochemical responses after 3-month antiviral treatment. Furthermore, the response states were maintained till the follow-up endpoint. However, in the non-antiviral group, HBV DNA replication resulted in higher levels of ALT and AST compared to the baseline values (P < 0.05). In the antiviral group, PVD, PV-CI, HV-DI, vWF-Ag and sCD163 were all significantly reduced than the baseline values (P < 0.05), and PVV was significantly increased than the baseline value (P < 0.05). Conclusions Antiviral therapy could effectively suppress hepatocyte inflammation and alleviate the dysfunction of intrahepatic vascular endothelial and hepatic macrophages, which might improve hepatic hemodynamic function in HBV-related cirrhosis.

Long-term nucleoside analogue therapy can lead effective HBV DNA inhibition in patients with chronic HBV infection in immune tolerate phase

2020 ◽  
Author(s):  
YAYUN LIU ◽  
XueSong Liang ◽  
AiJing Xu ◽  
Hao Xu ◽  
Jiao Yu ◽  
...  
Keyword(s):  
Seroconversion Rate ◽  
Hbv Dna ◽  
Efficacy And Safety ◽  
Limit Of Quantification ◽  
Start Date ◽  
Hbeag Loss ◽  
Hbsag Seroconversion ◽  
Dna Inhibition

Abstract Background and Aims The efficacy and safety of long-term antiviral therapy with nucleoside analogues (NAs) for chronic hepatitis B (CHB) patients in immune tolerate (IT) phase is uncertain.We retrospectively evaluated the efficacy and safety of 61 CHB patients in IT phase receiving NAs therapy from 2013 through 2018. Methods We performed a retrospective study of CHB patients who had high HBV DNA, normal or minimum alanine aminotransferase (ALT), liver biopsy confirmed light necro-inflammation and received NAs therapy from 2012 through 2018.All patients received NAs at least 12 months. Patients on-treatment monitoring were in accordance with the roadmap concept and were followed after their treatment start date to the treatment end date (if any) or 6 years at least once every 6 months. The median follow-up time was 36(16; 52) months. We assessed the virological response (the proportions of patients with plasma HBV DNA loads less than the limit of quantification,100IU/ml) and serological endpoints (HBeAg loss and seroconcersion to anti-HBe, and HBsAg loss and seroconversion to anti-HBs). Safety and tolerability, including serious events, were regularly assessed. Results At 48 weeks on treatment, 55.6%(95%confidence interval(CI):37.0-70.0%) patients with CHB in IT phase achieved HBV DNA less than quantitative limit(<100IU/ml), and the accumulate proportion of patients who achieved HBV DNA less than quantitative limit was 76.7%(95%CI: 58-90.0%) and 95.8%(95%CI: 79-100%) at 96 weeks and ≥144weeks on treatment, respectively. The HBeAg loss or seroconversion rate in patients with CHB in IT phase on NAs treatment at 48, 96 and ≥144weeks was 2.7%(95%CI: 0-14.0%), 13.3% (95%CI: 4-31.0%) and 29.2%(95%CI: 13-51%), respectively. During the study only one patient achieved HBsAg seroconversion after 3years NAs therapy and only one patient experienced drug-related breakthrough during the study. Conclusion Patients with CHB in IT phase have relatively preferable safety and HBV DNA inhibition efficacy on long-term NAs treatment.

scholarly journals TDF Monotherapy Is Effective Regardless of Prior Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patients in China

2017 ◽  
Vol 2017 ◽  
pp. 1-8
Author(s):  
Mingxing Huang ◽  
Guoli Lin ◽  
Hong Shi ◽  
Yuankai Wu ◽  
Yusheng Jie ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Baseline Level ◽  
Independent Predictor ◽  
Hbeag Seroconversion ◽  
Hbv Dna ◽  
Antiviral Effects ◽  
Negative Time

Background/Aims. Many patients had to transfer to tenofovir disoproxil fumarate (TDF) if there is other nucleos(t)ide analogue (NA) resistance. We aimed to investigate antiviral effects of TDF monotherapy between NA-naive and NA-experienced chronic hepatitis B (CHB) patients in China. Methods. A total of 102 NA-naive and NA-experienced CHB patients with TDF monotherapy (300 mg/day) were retrospectively analyzed for useful parameters up to 72 weeks. Results. There were 36 and 66 patients with matched HBV DNA baseline level in NA-naïve and NA-experienced group, respectively. There were no significant differences between NA-naïve and NA-experienced groups in HBV DNA levels (all P>0.05) and HBV DNA undetectable rates (all P>0.05) at all time points. At the end of follow-up, HBV DNA undetectable rates in NA-naïve and NA-experienced group were 96.2% (25/26) and 91.8% (45/49), respectively (P=0.476). Baseline HBV DNA level was the only independent predictor for HBV DNA negative time (P=0.018). In addition, 27.8% (5/18) and 11.4% (4/35) achieved HBeAg seroconversion at the end of the follow-up, respectively (P=0.133). Conclusions. TDF monotherapy was effective regardless of prior NA experienced. Baseline HBV DNA was a key predictive factor for HBV DNA negative time in TDF monotherapy.

EFFICACY OF TENOFOVIR IN PATIENTS OF HBV-RELATED CIRRHOSIS

2016 ◽  
pp. 25-29
Author(s):  
Van Huy Tran ◽  
Thi Huyen Thuong Nguyen
Keyword(s):  
Side Effects ◽  
Serum Creatinine ◽  
Key Words ◽  
Tenofovir Disoproxil Fumarate ◽  
Hbv Dna ◽  
Treatment Side Effects ◽  
Background Data ◽  
Key Words Cirrhosis

Background: Data about efficacy of Tenofovir in patients of HBV –related cirrhosis in Vietnam was still limited. This study is aimed at: - evaluating the clinical, biochemical, virological and Child-Pugh score responses 3,6,9 months after Tenofovir therapy; - assessing possible side effects of tenofovir. Patients and methods: 40 patients with HBV-related cirrhosis were enrolled. All has received Tenofovir disoproxil fumarate 300mg/day. Follow-up after 3,6 and 9 months. Results: Anorexia, oedema and ascites were significantly improved after treatment. HBV DNA became undetectable in 92.5%, 94.55 and 100% after 3,6 and 9 months, respectively. Child- Pugh score was improved after treatment (5.94±0.22 after treatment vs 7.47±0.28 before treatment). Side effects were minors (nausea, vomiting). No case of increase in serum creatinine was found. Conclusion: Tenofovir showed effective and safe in patients of HBV-related cirrhosis. Key words: Cirrhosis, tenofovir, HBV. Key words: cirrhosis, tenofovir, HBV

scholarly journals Lingmao Formula Combined with Entecavir for HBeAg-Positive Chronic Hepatitis B Patients with Mildly Elevated Alanine Aminotransferase: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Xiao-Jun Zhu ◽  
Xue-Hua Sun ◽  
Zheng-Hua Zhou ◽  
Shun-Qing Liu ◽  
Hua Lv ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Treatment Group ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Alanine Aminotransferase ◽  
Hbv Dna ◽  
Control Group ◽  
Hbeag Loss ◽  
Histological Improvement ◽  
Positive Chronic Hepatitis

Objective. To determine the efficacy and safety of Lingmao Formula combined with entecavir for HBeAg-positive chronic hepatitis B patients with mildly elevated alanine aminotransferase (ALT).Methods. 301 patients were randomly assigned to receive Lingmao Formula combined with entecavir (treatment group) or placebo combined with entecavir (control group) for 52 weeks. The outcomes of interest included the reduction of serum HBV DNA level, HBeAg loss, HBeAg seroconversion, ALT normalization, and histological improvement.Results. The mean decrease of serum HBV DNA level from baseline and the percentage of patients who had reduction in serum HBV DNA level ≥2 lg copies/mL in treatment group were significantly greater than that in control group (5.5 versus 5.4 lg copies/mL,P=0.010; 98.5% versus 92.6%,P=0.019). The percentage of HBeAg loss in treatment group was 22.8%, which was much higher than a percentage of 12.6% in control group (P=0.038). There was no significant difference between the two groups in histological improvement. Safety was similar in the two groups.Conclusions. The combination of Lingmao Formula with entecavir could result in significant decrease of serum HBV DNA and increase of HBeAg loss for HBeAg-positive chronic hepatitis B patients with mildly elevated ALT without any serious adverse events. Clinical trial registration number isChiCTR-TRC-09000594.

Simplified follow-up of patients with mild chronic hepatitis C in areas with limited access to antiviral therapy

2019 ◽  
Vol 51 (6) ◽  
pp. 875-881
Author(s):  
Sabela Lens ◽  
Ferran Torres ◽  
Martin Bonacci ◽  
Concepció Bartres ◽  
Anna Pocurull ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Chronic Hepatitis C ◽  
Limited Access
Sign in / Sign up

Export Citation Format

Share Document